Abstract
Background: The determination of cardiac troponins is routinely used for rule in/out, risk stratification, and follow-up of patients with acute coronary artery syndrome. We evaluated the analytical and clinical performance of the advanced immunoassay for troponin I (cTnI) carried out on an AxSYM platform (Abbott Diagnostic Division) and compared these characteristics to those of the previous version of this assay and to cTnI on the Access 2 immunoassay system (Beckman Coulter, Inc.).
Methods: We assayed plasma samples from healthy subjects (n=66) and cardiac patients (n=132) using AxSYM Plus system assays called the old (OLD AxSYM) and advanced TnI (ADV AxSYM) methods and using an Access system.
Results: An improvement in analytical sensitivity (detection limit) was observed for the advanced cTnI AxSYM compared to the previous method (0.014 vs. 0.31μg/L), while the cTnI value for the 10% CV (i.e., functional sensitivity) was 0.41μg/L for the ADV and 1.9μg/L for the OLD method. The kinetics of cTnI release was similar, as evaluated in 25 patients with typical acute myocardial infarction (AMI). A close linear relationship was found between the two methods on the AxSYM system (OLD cTnI=7.436+6.858 ADV cTnI; R=0.968, n=214) and with the Access system (OLD AxSYM=7.154+7.9 Access, R=0.876, n=158; ADV AxSYM=0.23+1.209 Access, R=0.927, n=160). However, wide bias was found between the OLD and ADV AxSYM methods (mean difference 118.4μg/L, p<0.0001), while more similar results were found between the ADV AxSYM and Access methods (mean difference 2.6μg/L, corresponding to a mean percentage difference of 17%, p<0.0001). In 106 patients with symptomatic rheumatoid arthritis with high rheumatoid factor (RF) concentration, the mean cTnI measured by the ADV AxSYM method was 0.009±0.031μg/L (range 0–0.23μg/L) with a significant correlation (R=0.316, p=0.001) between cTnI and RF values. Furthermore, in 60 of these serum samples the cTnI concentration was also measured using the Access method; significant correlation with the values found by the ADV AxSYM method was observed (R=0.468, p=0.0002).
Conclusions: The present study indicates that the AxSYM Troponin-I ADV immunoassay shows improved analytical sensitivity compared to the OLD AxSYM method, as well as very similar clinical results to those determined using the Access method.
Clin Chem Lab Med 2006;44:1022–9.
References
1. Alpert J, Thygesen K, for the Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36:959–69.10.1016/S0735-1097(00)00804-4Search in Google Scholar
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Unstable Angina): ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106:1893–2000.10.1161/01.CIR.0000037106.76139.53Search in Google Scholar
3. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. Circulation 2003; 108:2543–9.10.1161/01.CIR.0000100560.46946.EASearch in Google Scholar
4. Christenson RH, Duh SH, Apple FS, Bodor GS, Bunk DM, Dalluge J, et al. Standardization of cardiac troponin I assays: round robin of ten candidate reference materials. Clin Chem 2001; 47:431–7.10.1093/clinchem/47.3.431Search in Google Scholar
5. Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004; 50:327–32.10.1373/clinchem.2003.026815Search in Google Scholar
6. Apple FS, Murakami MM. The diagnostic utility of cardiac biomarkers in detecting myocardial infarction. Clin Cornerstone 2005; 7(Suppl 1):S25–30.10.1016/S1098-3597(05)80011-0Search in Google Scholar
7. Apple FS. Analytical issues for cardiac troponin. Prog Cardiovasc Dis 2005; 47:189–95.10.1016/j.pcad.2004.07.002Search in Google Scholar PubMed
8. Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001; 39:175–9.10.1515/cclm.2001.39.2.175Search in Google Scholar PubMed
9. Abbott Laboratories. AxSYM Troponin-I ADV assay package insert, REF 2J44 34-3355/R2. Abbott Park, IL: Abbott Laboratories, Diagnostic Division, 2004.Search in Google Scholar
10. Baevsky RH, Kapur RK, Smithline HA. Beckman Access versus the Bayer ACS:180 and the Abbott AxSYM cardiac troponin-I real-time immunoassays: an observational prospective study. BMC Emerg Med 2004; 4:1–8.10.1186/1471-227X-4-2Search in Google Scholar PubMed PubMed Central
11. Apple FS, Quist H, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49:1331–6.10.1373/49.8.1331Search in Google Scholar PubMed
12. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 2002; 144:981–6.10.1067/mhj.2002.124048Search in Google Scholar
13. Beckman Instruments. AccuTnI Beckman Access Troponin I assay package insert (bulletin 9761). Beckman Coulter, Inc, 4300 Harbor blvd., Fullerton, CA 92835, USA: Beckman Instruments, 2002.Search in Google Scholar
14. Ritter D, Lee PA, Taylor JF, Hsu L, Cohen JD, Chung HD, et al. Troponin I in patients without chest pain. Clin Chem 2004; 50:112–9.10.1373/clinchem.2003.016311Search in Google Scholar
15. Qiu KY, Sokolowski L, Bouma SR, Sumerdon GA, Biegalski TT, Gardiner ME, et al. Determination of sensitivity and specificity for the AxSYM troponin-I ADV assay at three clinical reference points [abstract]. Clin Chem 2005; 51(Suppl 6):A17–8.Search in Google Scholar
16. NCCLS. Evaluation of precision performance of clinical chemistry devices; approved guideline. Document EP5-A. Wayne, PA: NCCLS, 1999.Search in Google Scholar
17. Apple FS. Clinical and analytical standardization issues confronting cardiac troponin I. Clin Chem 1999; 45:18–20.10.1093/clinchem/45.1.18Search in Google Scholar
18. Bunk DM, Welch MJ. Characterization of a new certified reference material for human cardiac troponin I. Clin Chem 2006; 52:212–9.10.1373/clinchem.2005.051359Search in Google Scholar
19. Krahn J, Parry D, Leroux M, Dalton J. High percentage of false positive cardiac troponin I results in patients with rheumatoid factor. Clin Biochem 1999; 32:477–80.10.1016/S0009-9120(99)00044-2Search in Google Scholar
20. Onuska KD, Hill SA. Effect of rheumatoid factor on cardiac troponin I measurements using two commercial measurement systems. Clin Chem 2000; 46:307–8.10.1093/clinchem/46.2.307Search in Google Scholar
21. Dasgupta A, Banerjee SK, Datta P. False-positive troponin I in the MEIA due to the presence of rheumatoid factors in serum. Am J Clin Pathol 1999; 112:753–6.10.1093/ajcp/112.6.753Search in Google Scholar PubMed
22. Katwa G, Komatireddy G, Walker SE. False positive elevation of cardiac troponin I in seropositive rheumatoid arthritis. J Rheumatol 2001; 28:2750–1.Search in Google Scholar
23. Kenny PR, Finger DR. Falsely elevated cardiac troponin-I in patients with seropositive rheumatoid arthritis. J Rheumatol 2005; 32:1258–60.Search in Google Scholar
24. Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Hughes EA, et al. Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden? J Am Coll Cardiol 2006; 47:1169–74.10.1016/j.jacc.2005.10.059Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
